ClinPhone has hired former Healthcare Technology Systems (HTS) vice president Keith Wenzel to optimise the use of licenced HTS clinical assessments within clinical trials
ClinPhone has hired former Healthcare Technology Systems (HTS) vice president Keith Wenzel to optimise the use of licenced HTS clinical assessments within clinical trials.
ClinPhone recently secured an exclusive, worldwide perpetual license for the use of HTS's assessments on any device or medium used in phase I-IV clinical trials funded by pharmaceutical, biotechnology or medical device companies.
"We are delighted to bring Keith on board - he is a noted expert in the use of technology to collect patient reported outcomes," said Howard Goldberg, vice president and general manager of ClinPhone.
"Keith brings our clients over 15 years of industry experience as well as extensive knowledge in validating computer-administered clinical assessments and designing information systems that emphasise efficiencies".
Wenzel will be based at the company's Chicago office.
His initial assignment as project consultant - patient rated assessments will be to help ClinPhone build on the expertise it already has within the electronic patient reported outcomes arena.
He will act as an information resource for operations staff and for business development managers ensuring a smooth transition from sale through project delivery.
He will also interface directly with existing and potential customers to provide information and expertise on the use of the patient rated assessments.
"I have enjoyed working with ClinPhone as a partner over the past few years and I am happy to be working even more closely with my colleagues," Wenzel commented.
"My new role will build on my experience with HTS and will include client consultation for electronic patient assessments and liaison with HTS physicians for the licensed assessments," he explained. ClinPhone claims to be the most experienced clinical technology provider in the pharmaceutical industry.
It counts the vast majority of pharma and biotech companies as clients, including preferred supplier agreements with 15 of the top 20 pharmaceutical companies.
